Neuren Pharmaceuticals Statistics

Total Valuation

Neuren Pharmaceuticals has a market cap or net worth of 2.54 billion. The enterprise value is 2.31 billion.

Market Cap	2.54B
Enterprise Value	2.31B

Important Dates

The next estimated earnings date is Monday, July 29, 2024.

Earnings Date	Jul 29, 2024
Ex-Dividend Date	n/a

Share Statistics

Neuren Pharmaceuticals has 127.27 million shares outstanding. The number of shares has increased by 1.64% in one year.

Shares Outstanding	127.27M
Shares Change (YoY)	+1.64%
Shares Change (QoQ)	+0.80%
Owned by Insiders (%)	13.29%
Owned by Institutions (%)	17.53%
Float	110.35M

Valuation Ratios

The trailing PE ratio is 16.61 and the forward PE ratio is 38.46.

PE Ratio	16.61
Forward PE	38.46
PS Ratio	10.95
PB Ratio	12.38
P/FCF Ratio	13.74
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.60, with an EV/FCF ratio of 12.51.

EV / Earnings	14.72
EV / Sales	9.97
EV / EBITDA	11.60
EV / EBIT	11.60
EV / FCF	12.51

Financial Position

The company has a current ratio of 5.78

Current Ratio	5.78
Quick Ratio	5.68
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-35.03

Financial Efficiency

Return on equity (ROE) is 76.55% and return on invested capital (ROIC) is 74.35%.

Return on Equity (ROE)	76.55%
Return on Assets (ROA)	63.35%
Return on Capital (ROIC)	74.35%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	1.33
Inventory Turnover	n/a

Taxes

In the past 12 months, Neuren Pharmaceuticals has paid 48.04 million in taxes.

Income Tax	48.04M
Effective Tax Rate	23.42%

Stock Price Statistics

The stock price has increased by +70.26% in the last 52 weeks. The beta is 2.03, so Neuren Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	2.03
52-Week Price Change	+70.26%
50-Day Moving Average	20.05
200-Day Moving Average	18.25
Relative Strength Index (RSI)	49.99
Average Volume (20 Days)	454,331

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Neuren Pharmaceuticals had revenue of 231.93 million and earned 157.08 million in profits. Earnings per share was 1.20.

Revenue	231.93M
Gross Profit	205.17M
Operating Income	199.23M
Pretax Income	205.12M
Net Income	157.08M
EBITDA	199.25M
EBIT	199.23M
Earnings Per Share (EPS)	1.20

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	228.54M
Total Debt	n/a
Net Cash	228.54M
Net Cash Per Share	1.80
Equity (Book Value)	205.21M
Book Value Per Share	1.61
Working Capital	204.39M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 184.93 million and capital expenditures -40,000, giving a free cash flow of 184.89 million.

Operating Cash Flow	184.93M
Capital Expenditures	-40,000
Free Cash Flow	184.89M
FCF Per Share	1.41

Full Cash Flow Statement

Margins

Gross margin is 88.47%, with operating and profit margins of 85.90% and 67.73%.

Gross Margin	88.47%
Operating Margin	85.90%
Pretax Margin	88.44%
Profit Margin	67.73%
EBITDA Margin	85.91%
EBIT Margin	85.90%
FCF Margin	79.72%

Dividends & Yields

Neuren Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.64%
Shareholder Yield	-1.64%
Earnings Yield	6.18%
FCF Yield	7.28%

Analyst Forecast

Price Target	28.56
Price Target Difference	43.52%
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on November 21, 2017. It was a reverse split with a ratio of 1:20.

Last Split Date	Nov 21, 2017
Split Type	Reverse
Split Ratio	1:20